Voluntary Limits On Antibacterial Discharges Increase As Fear Of Resistance Grows
Pharmaceutical companies are ratcheting up voluntary efforts to control discharges of antimicrobials from their plants and those of their active pharmaceutical ingredient suppliers so they won’t contribute to antimicrobial resistance. But will it be enough to fend off regulation in countries like India?
You may also be interested in...
Objections to 15 February reporting date established in draft guidance spurred rare last-minute notice assuring industry that it was a non-binding recommendation, not a requirement. Action reflects confusion that can arise in interpreting policy guidance.
The COVID-19 pandemic has both caused problems such as reduced preventive maintenance and exacerbated other issues, such as slowing recovery from extreme weather events, according to Resilinc CEO.
As omicron COVID-19 variant recedes, GAO shares thoughts on FDA’s plans for unannounced foreign inspections and translation services pilots. The report also details agency efforts to fill vacant foreign inspection positions.